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Abstract
Background: Chlamydophila pneumoniae and Mycoplasma pneumoniae are associated with acute
exacerbation of bronchial asthma (AEBA). The aim of this study was to evaluate the correlation
between these acute bacterial infections and the severity of AEBA.
Methods:  We prospectively analysed consecutive patients admitted to the Emergency
Department with acute asthma exacerbation. In every patient peak expiratory flow (PEF)
measurement was performed on admission, and spirometry during follow-up. Serology for
Chlamydophila and Mycoplasma pneumoniae was performed on admission and after 4–8 weeks.
Results: Fifty-eight patients completed the study. Acute atypical infections (AAI) was observed in
22/58 cases; we found single acute C. pneumoniae in 19 cases, single acute M. pneumoniae in 2
cases, and double acute infection in one case. Functional impairment on admission was greater in
patients with AAI than in patients without AAI (PEF 205 ± 104 L/min vs 276 ± 117 p = 0.02) and
persisted until visit 2 (FEV1% 76.30 ± 24.54 vs FEV1% 92.91 ± 13.89, p = 0.002). Moreover, the
proportion of patients who presented with severe AEBA was significantly greater in the group with
AAI than in the group without AAI (15/22 vs 12/36, p = 0.01; OR 4.29, 95% CI 1.38–13.32).
Conclusion: Our data suggest an association between acute atypical infection and a more severe
AEBA.
Background
Acute exacerbations of bronchial asthma (AEBA) repre-
sent an important healthcare problem, accounting for a
high rate of morbidity and mortality. Furthermore,
increased disease burden and asthma symptoms fre-
quently persist for at least 1 month after emergency
department discharge following an asthma exacerbation
[1].
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The role of respiratory infections in asthma is well known;
the micro-organisms most commonly involved are viruses
and atypical bacteria, such as Mycoplasma pneumoniae and
Chlamydophila pneumoniae [2,3].
C. pneumoniae and M. pneumoniae represent an important
cause of human respiratory tract diseases. These agents are
involved in upper respiratory tract infections acute bron-
chitis and exacerbations of chronic bronchitis, and pneu-
monia [4-6]. C. pneumoniae infection has been implicated
in severe chronic asthma [7-9], whereas other groups
demonstrated that C. pneumoniae and  M. pneumoniae
causes AEBA both in children and adults [3,10,11]. A
recent review indicates that the high proportion of these
studies that have reported a link between AEBA and C.
pneumoniae and/or M. pneumoniae infection suggests that
these pathogens may play a significant role in such exac-
erbations [12].
However, to date the relationship between acute atypical
infection (AAI) and the degree of severity of acute asthma
exacerbation has not been yet evaluated. Should this asso-
ciation be observed, then antibiotic treatment against
atypical bacteria could play a role in the management of
acute asthma attack.
Therefore, the aim of this study is to evaluate a possible
correlation between acute Mycoplasma  and  Chlamydia
pneumoniae infection and the severity of manifestation of
acute asthma exacerbation.
Methods
This was an observational prospective study of consecu-
tive patients with acute exacerbation of asthma admitted
to the Emergency Room of Fondazione IRCCS Ospedale
Maggiore Policlinico, Mangiagalli e Regina Elena Hospi-
tal, Milan, Italy, between January 2004 and December
2004. Acute exacerbation of bronchial asthma (AEBA)
was defined as following: episodes of rapidly progressive
increase in shortness of breath, cough, wheezing, or chest
tightness, or some combination of these symptoms neces-
sitating a non-scheduled visit, and associated to a decrease
of respiratory airflow quantified by measurements of peak
expiratory flow (PEF) or FEV1 [13]. Severe exacerbation of
asthma was defined when PEF on admission was <50%
according to BTS criteria [14]. We chose the PEF value
measurement as the only criterion for acute severe asthma
exacerbation in Emergcency Room since it is a direct and
reproducible measurement easily controlled in the fol-
low-up.
Subjects satisfying criteria for acute exacerbation of
asthma were eligible for the study if all the following
inclusion criteria were fulfilled: 1) age > 18 yrs; 2) history
of typical bronchial asthma > 6 mo and 3) smoking his-
tory < 10 pack/yrs.
Patients with a radiological diagnosis of pneumonia or
with impaired consciousness on admission were excluded
from the study.
On admission, past medical history and active medica-
tions were collected; every patient underwent the follow-
ing examinations: PEF measurements (best out of three),
spirometry, an oropharyngeal swab specimens and a
blood sample for serologic testing.
Patients were treated according to British Thoracic Society
guidelines, considering the degree of severity [14]. In par-
ticular, patients presenting with a severe acute attack were
treated with systemic steroids, whereas those with a non-
severe attack were treated with topic steroids.
Follow-up was performed at 2–4 days (Visit 1), at 10–14
days (Visit 2), and at 4–8 weeks (Visit 3), including func-
tional evaluation by spirometry. A second blood sample
was drawn for serologic testing (convalescence phase) 4–
8 weeks after the admission.
Serologic tests included IgG and IgM for C. pneumoniae
(microimmunofluorescence test, Labsystems, Helsinki,
Finland), and IgG and IgM for M. pneumoniae (ELISA test,
Pantec, Turin, Italy). On oropharyngeal swab specimens a
nested-polymerase chain reaction (PCR) technique for the
detection of C. pneumoniae DNA [15] was performed.
Acute C. pneumoniae infection was defined as IgM titre ≥
1:16 or a fourfold increase in the specific IgG [16]. Acute
M. pneumoniae infection was defined as IgM titre ≥ 1:16 or
a fourfold increase in the specific IgG [17]. The person
performing the MIF test was blinded to the patient diag-
nosis and characteristics.
Flowchart of the study Figure 1
Flowchart of the study.Respiratory Research 2008, 9:48 http://respiratory-research.com/content/9/1/48
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Patients were divided into two groups according to the
presence or the absence of acute Chlamydia and/or Myco-
plasma pneumoniae infection (AAI). The two groups were
compared according to the degree of functional impair-
ment.
A sub-analysis was performed among the group of
patients with acute atypical infection in order to evaluate
the degree of functional impairment between the two dif-
ferent pathogens.
Local IRB review was performed and informed consent
was obtained from all patients on admission to the study.
Statistical analysis
All data were statistically analyzed with SPSS version 10.1
(Chicago, Il). A descriptive statistics at baseline with con-
tinuous data expressed as a mean or median (depending
on distribution) ± SD was performed, and data were com-
pared between the group with AAI and the group without
AAI using ANOVA test. Baseline categorical data between
the two groups were compared by the χ2 test or Fisher's
exact test when appropriate. p value < 0.05 was considered
statistically significant. Among the group with AAI, the
same test was applied to compare continuous data
between the group with acute C. pneumoniae infection and
the group with acute M. pneumoniae infection.
Results
Sixty-nine patients were admitted to our Emergency
Room and screened for the protocol. Two patients were
excluded for impaired consciousness, 2 were excluded for
radiological diagnosis of pneumonia, and 7 refused con-
sent. Fifty-eight patients have been enrolled. Ten patients
have been admitted to hospital, and 48 have been dis-
charged. All 58 patients completed the follow-up (Figure
1).
Thirty-four (59%) were males, mean age was 38.1 ± 11.8
yrs, 2 were current smokers, 30 (52%) had a history of
atopy, 11 (19%) were on inhaled corticosteroids before
exacerbation, and 19 (33%) had a recent history of acute
upper respiratory infection. Mean PEF on admission was
253.8 ± 121.1 (58 pts) and mean FEV1 (30 pts) 1.39 ±
0.63; spirometry was not performed in all patients
because, in keeping with patient's best interest, treatment
was not delayed and in some cases was initiated before
spirometry.
Acute serologically demonstrated atypical infection was
found in 22/58 patients (38%). Single acute C. pneumonia
infection was observed in 19 out of 22 patients (86%),
with a four-fold increase in IgG titre after 4–8 weeks; no
IgM titre ≥ 1:16 was found.
Serologic evidence of single acute M. pneumoniae infection
was found in only 2 out of 22 patients (9%) with a posi-
tive IgM titre. In one case, the acute M. pneumoniae infec-
tion was associated with acute C. pneumoniae infection
(Table 1). PCR for C. pneumoniae DNA oropharyngeal
swab was positive in 13/20 (sensitivity = 65%), and in 1/
38 cases without acute C. pneumoniae infection (specificity
= 93.7%).
Demographic and history characteristics distribution
between the two groups is shown in Table 2. On admis-
sion, PEF values in the 22 subjects with serological AAI
were significantly lower when compared with measure-
ments in the 36 patients without AAI (205 ± 104 vs 277 ±
117, p = 0.023). In addition, mean predicted PEF values
according to sex, age, and height was comparable between
subjects with and without AAI (546 ± 85 vs 510 ± 102, p
= 0.159). However, the mean PEF percentage values of the
predicted values were significantly lower in subjects with
acute atypical infection (38.3 ± 18.3 vs 55.3 ± 19,5, p =
0.002).
In the subgroup of thirty patients where spirometry was
performed on admission, FEV1% predicted values in the
11 patients with AAI were significantly lower than in the
other 19 subjects without AAI (39.73 ± 19.64 vs 58.53 ±
20,43, p = 0.02).
Considering the severity of acute attacks according to BTS
criteria [14] (severe = PEF <50%, 27 patients; non-severe,
PEF > 50%, 31 patients); the proportion of patients with
acute severe attack was significantly greater in the group
with AAI than in the group without AAI (15/22 vs 12/36,
p = 0.010; OR 4.29, 95% CI 1.38–13.32) (Table 3).
During follow-up, spirometry was performed in all 58
patients. At Visit 1, the 22 patients with AAI showed sig-
nificantly lower FEV1% values than patients without AAI
Table 1: Serologically demonstrated acute atypical infection (AAI) in the study population (22/58 patients)
Pts with AAI 22
C. pneumoniae 19 GMT IgG on admission 38.4 GMT IgG after 4–8 weeks 442.48
M. pneumoniae 2 IgM positive
M. pneumoniae and C. pneumoniae 1 IgM positive IgG on admission 1:64 IgG after 4–8 weeks 1:512Respiratory Research 2008, 9:48 http://respiratory-research.com/content/9/1/48
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(70.91 ± 25.60 vs 89.14 ± 17.07, p = 0.002). At visit 2 the
FEV1% difference remained statistically significant
(patients with AAI: 76.30 ± 24.54 vs patients without AAI:
92.91 ± 13.89, p = 0.002), whereas at visit 3 the difference
was no longer statistically significant (see Table 3).
Discussion
The aim of this study was to verify whether acute M. pneu-
moniae and C. pneumoniae infection is associated with the
severity of acute asthma attack. We found that patients
with serologically demonstrated AAI presented in the
Emergency Room with a higher degree of functional
impairment. However, in our case series, the role of C.
pneumoniae was predominant, since we found only two
cases of single acute M. pneumoniae infection. The inci-
dence of these two bacteria observed in our study is differ-
ent from previous published data [3]. This difference may
be related to the long epidemic cycle of the two bacteria
and to the difference of our study design that was not an
epidemiological study.
The relationship between respiratory infections and
asthma exacerbation has been observed since the '80s in
both children and adults. First reports analysed the role of
respiratory viruses, whereaslater on several observations
pointed out the possible involvement of atypical bacteria
in asthma, particularly M. pneumoniae and C. pneumoniae
both in chronic stable asthma and in acute exacerbations
[2,3,10,11,15,18-20]. Subsequently, it has been shown
that C. pneumoniae chronic infection is associated with a
more severe chronic functional impairment both in chil-
dren and adults [7-9,21]. Interestingly, Wark et al. [22]
showed that patients with acute asthma and an acute rise
in C. pneumoniae antibody levels exhibit more intense air-
way inflammation compared to subjects with no antibody
response. Recent evidence indicates that C. pneumoniae
elements, through the activation of transcription factors
(such as nuclear factor κB), are responsible for the activa-
tion of most cellular elements in bronchial tissue (epithe-
lium, endothelium, monocytes/macrophages, smooth
muscle cells), resulting in a cascade of cytokine release
and adhesion molecule up regulation which favours cellu-
lar influx into the airways, persistent infection, and airway
remodelling [12,23,24]. Data concerning the pathoge-
netic role of M. pneumoniae in asthma are few. It is been
shown that Mycoplasma infection induces a secretion of IL-
8 and TNF-α by human lung epithelial cells in vitro [25].
Furthermore, a potential interaction between infection
and allergy is suggested by the demonstration that, in tis-
sue biopsy in patients with asthma and positive PCR for
M. pneumoniae and C. pneumoniae, there is evidence of a
greater mast cell tissue infiltration than in those without
infection [26].
To our knowledge, no studies have evaluated the relation-
ship between these two atypical bacteria and the severity
of functional impairment during AEBA.
Therefore, we investigated whether AAI might be associ-
ated with an acute asthma exacerbation with a particularly
Table 3: Lung function in the two different groups of patients with acute atypical infection (AAI) and patients without AAI during the 
study period.
Patients with AAI (22) Patients without AAI (36) p
PEF predicted (L/min) 546.9 ± 85.4 509.8 ± 101.9 0.159
PEF admission (L/min) 205.9 ± 104.1 276.9 ± 117.3 0.023
PEF % of predicted on admission 38.3 ± 18.3 55.3 ± 19.5 0.002
FEV1% on admission 39.73 ± 19.64 (11 pts) 58.53 ± 20.43 (19 pts) 0.02
FEV1% Visit 1 (2–4 days) 70.91 ± 25.6 89.14 ± 17.07 0.002
FEV1% Visit 2 (10–14 days) 76.30 ± 24.54 92.91 ± 13.89 0.002
FEV1% Visit 3 (4–8 weeks) 85.05 ± 19.13 92.26 ± 14.44 0.114
Acute severe attack (number of patients) 15 12 0.01
OR 4.29, 95% CI 1.38–13.32
Table 2: Demographic and history characteristics of the study population according to acute atypical infection (AAI)
patients with AAI (22) patients without AAI (38) p
Males 13 18 0.501
Age (yrs) 39.3 ± 13.7 37.4 ± 10.7 0.546
Current smokers 1 1 0.631
Atopy 12 18 0.737
Inhaled steroids (before exacerbation) 5 6 0.568
Clinical symptoms of acute upper airway infection 7 12 0.905Respiratory Research 2008, 9:48 http://respiratory-research.com/content/9/1/48
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severe functional impairment. We found that patients
with AAI exhibited on admission a more severe functional
impairment. Interestingly, the majority of these presented
to the Emergency Room with an acute attack classified as
"severe" according to the BTS criteria, as opposed to
patients without AAI. In addition, to a more severe asthma
attack presentation, these patients also showed a slower
rise of FEV1 during follow-up when compared with the
group without AAI. A recent study showed that C. pneumo-
niae infection enhanced the proliferation and survival of
immune and inflammatory cells, resulting in steroid
resistance [27]. This phenomenon might explain the
slower clinical improvement in these patients with AAI,
where the presence of C. pneumoniae was predominant.
The first limitation of our study is that the diagnosis of
AAI remains difficult because of the absence of well stand-
ardised diagnostic tests. However, for the diagnosis of C.
pneumoniae infection we used the microimmunofluores-
cence (MIF) test that is considered the "gold standard",
despite its many known limitations including subjectivity
(operator dependence) [16,28]. Whilst serology is an indi-
rect measure of infection, direct detection of C. pneumo-
niae and M. pneumoniae can be achieved by culture of the
organisms or detection of DNA by PCR. However, culture
has very poor sensitivity and is rarely successful, while
PCR testing methods are not yet standardized [16,28]. In
fact, we found C. pneumoniae PCR positivity in only
around 65% of patients with serologically demonstrated
acute C. pneumonia infection. Another limitation of our
study is the small sample size, characterising a typical pre-
liminary study. A further weakness of our work is the use
of PEF expressed as a percentage of predicted value and
not of the patient's previous best value, as suggested by
the BTS guidelines [14]. However, in patients admitted to
an Emergency Room the information about their best PEF
value is not always available. In this case, as suggested by
the guidelines, the percentage of predicted value could be
a guide to the severity.
Conclusion
Our data suggest an association between AAI and the
severity of acute asthma attack. Considering that all
patients eventually reached similar FEV1 values, we sug-
gest that, in our study population, the diversity in exacer-
bation intensity may have been associated with the
presence of AAI. Taking into account the limited popula-
tion size in the study, our data should be confirmed by
further studies. Should the association between AAI and
severity of asthma exacerbation be confirmed in larger
case series, appropriate anti-atypical bacterial antibiotic
treatment may have to be considered in patients with
severe asthma exacerbations.
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